These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 33663881)

  • 1. Current status of oral anticoagulant adherence in Japanese patients with atrial fibrillation: A claims database analysis.
    Yagi N; Suzuki S; Nagai K; Tanaka T; Nagahama T; Arita T; Otsuka T; Yamashita T
    J Cardiol; 2021 Aug; 78(2):150-156. PubMed ID: 33663881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
    Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
    Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2017 Sep; 23(9):958-967. PubMed ID: 28854077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
    McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
    J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
    Mueller T; Alvarez-Madrazo S; Robertson C; Bennie M
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1378-1386. PubMed ID: 28752670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
    Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
    Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1027-1036. PubMed ID: 33822401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization outcomes of direct oral anticoagulants in Medicare patients.
    Arora P; Muehrcke M; Russell M; Ghanekar S
    Res Social Adm Pharm; 2023 Nov; 19(11):1424-1431. PubMed ID: 37429747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
    Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5-Year Retrospective Cohort Study.
    Aigami T; Ishigo T; Takada R; Yano T; Koyama M; Katano S; Fujii S; Fukudo M
    J Clin Pharmacol; 2023 Jun; 63(6):654-663. PubMed ID: 36609916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation.
    Fatima B; Mohan A; Altaie I; Abughosh S
    J Manag Care Spec Pharm; 2024 May; 30(5):408-419. PubMed ID: 38701026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
    Pham PN; Brown JD
    BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Charlton A; Vidal X; Sabaté M; Bailarín E; Martínez LML; Ibáñez L
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1210-1220. PubMed ID: 34464214
    [No Abstract]   [Full Text] [Related]  

  • 19. Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over.
    Cavillon Decaestecker M; Ferret L; Decaestecker K; Gautier S; Verdun S; Tsogli ES
    Drugs Aging; 2021 Oct; 38(10):939-950. PubMed ID: 34486094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
    Manzoor BS; Walton SM; Sharp LK; Galanter WL; Lee TA; Nutescu EA
    J Thromb Thrombolysis; 2017 Nov; 44(4):435-441. PubMed ID: 29027097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.